OncoMatch/Clinical Trials/NCT07070440
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Is NCT07070440 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including DZD6008 and Pemetrexed for non small cell lung cancer.
Treatment: DZD6008 · Pemetrexed · Carboplatin · Docetaxel — This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: EGFR tyrosine kinase inhibitor
Exception: treatment naive
Failure of prior 3 generations EGFR TKI or treatment naive
Lab requirements
Blood counts
Sufficient bone marrow or other organ reserve before first dosing
Sufficient bone marrow or other organ reserve before first dosing
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07070440 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior EGFR tyrosine kinase inhibitor disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR sensitizing mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages